Iovance Biotherapeutics’ (IOVA) Buy Rating Reiterated at Chardan Capital

Iovance Biotherapeutics (NASDAQ:IOVA)‘s stock had its “buy” rating reissued by Chardan Capital in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $16.00 price objective on the biotechnology company’s stock. Chardan Capital’s target price would suggest a potential upside of 334.43% from the stock’s current price.

A number of other equities research analysts also recently commented on IOVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday. UBS Group lifted their price target on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a “neutral” rating in a report on Thursday, March 5th. Truist Financial upgraded shares of Iovance Biotherapeutics to a “hold” rating in a report on Wednesday, March 25th. Wall Street Zen raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Citizens Jmp raised shares of Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price target for the company in a research report on Tuesday, March 3rd. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $8.88.

Iovance Biotherapeutics Trading Down 8.2%

Shares of NASDAQ IOVA traded down $0.33 during midday trading on Friday, reaching $3.68. 41,163,018 shares of the stock were exchanged, compared to its average volume of 15,335,350. The company has a market capitalization of $1.52 billion, a P/E ratio of -3.29 and a beta of 0.76. Iovance Biotherapeutics has a 52-week low of $1.64 and a 52-week high of $5.63. The stock has a 50 day moving average price of $3.47 and a 200-day moving average price of $2.75.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The business had revenue of $86.77 million during the quarter, compared to the consensus estimate of $81.61 million. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. On average, analysts forecast that Iovance Biotherapeutics will post -1.24 earnings per share for the current year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several institutional investors have recently bought and sold shares of the business. State Street Corp increased its holdings in Iovance Biotherapeutics by 51.5% in the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock valued at $55,041,000 after purchasing an additional 6,851,486 shares in the last quarter. Palo Alto Investors LP boosted its position in shares of Iovance Biotherapeutics by 122.1% in the third quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company’s stock worth $16,531,000 after buying an additional 4,188,803 shares during the period. HRT Financial LP boosted its position in shares of Iovance Biotherapeutics by 1,078.3% in the fourth quarter. HRT Financial LP now owns 4,356,010 shares of the biotechnology company’s stock worth $11,891,000 after buying an additional 3,986,314 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Iovance Biotherapeutics by 202.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock worth $19,239,000 after buying an additional 3,869,617 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Iovance Biotherapeutics by 13.1% in the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after buying an additional 3,148,096 shares during the period. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Zacks Research raised multiple near‑term and FY2028 EPS estimates (Q1 2026, Q2 2027, Q1 2028 and FY2028), trimming projected losses slightly — a fundamental improvement that can support the stock.
• Positive Sentiment: Unusually large options activity: traders bought ~23,006 call contracts (a ~213% jump vs. average), signaling increased bullish speculation or hedging interest in IOVA.
• Positive Sentiment: Positive press coverage highlights the company’s oncology focus and potential upside, which can attract longer‑term investors. Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?
• Positive Sentiment: Operational/clinical credibility boosted by coverage of Iovance’s Philadelphia manufacturing facility that converts immune cells into melanoma therapy — a tangible execution story for its cell‑therapy platform. Iovance’s Philadelphia facility transforms immune cells into lifesaving melanoma therapy
• Neutral Sentiment: Company remains unprofitable with consensus FY EPS around -$1.24 and negative margins/ROE; improved estimates are incremental rather than a move to profitability, which caps valuation support.
• Negative Sentiment: The stock is trading lower today on heavy volume (well above average), suggesting profit‑taking, option‑related hedging selling, or sector weakness is overriding the positive news flow.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.